From Editing Genes to Orchestrating Networks: CRISPR and the Future of Precision Oncology

The advent of CRISPR-based genome editing has transformed the conceptual framework of oncology—from descriptive molecular profiling to functional genome engineering. By enabling precise, programmable, and multiplex control of cancer-associated genes, CRISPR/Cas systems are reshaping how we model tumorigenesis, predict drug response, and design patient-tailored interventions. This Perspective discusses how CRISPR technologies are redefining precision oncology, the biological and ethical challenges that impede their clinical translation, and emerging strategies that integrate gene editing with immunotherapy, synthetic biology, and systems medicine. We argue that the future of cancer therapy lies not merely in editing genes but in orchestrating the dynamic networks that sustain malignancy.